Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Simone78
    Senior Member
    • Oct 2010
    • 208

    #1

    tagmentation of the 3'-end of cDNAs: which sequences are added?

    Hi!
    I want to sequence the 3'-end of all transcripts of a cell using the Nextera kit.
    The tagmentation rxn is done on full-lenght ds cDNA and since the oligo-dT used in the RT is biotinylated, I then expect to capture all the 3'-ends of the transcript using Dynabeads (and get rid of the rest).
    What is not clear to me is what the transposase is doing at the end of the transcript. Adding one adaptor? None?
    I expect the fragment to look like this after tagmentation:

    5’NNNNNNNNNNNNNNNNNNN--------------------------------AAAAAAAAAAACCCCCCCCCCCCCC-3’
    3’ NNNNNNNNNNN ------------------------AAAAAAAAAAACCCCCCCCCCCCCC-biot 5’

    where: N= sequence loaded on the transposase and attached to the target DNA
    A=poly-A tail
    C=custom adaptors

    If I then follow the Nextera protocol and do gap filling+PCR I get nothing...only adaptor dimers (i5-i7).
    Does anybody have experience with tagmentation of the 3'end of transcripts? I can't find any useful info on the web.
    Any help is appreciated! Thanks in advance!

Latest Articles

Collapse

  • SEQadmin2
    16S/ITS Profiling vs. Shotgun Metagenomics: What Changes in Your Workflow?
    by SEQadmin2




    NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...
    10-30-2026, 06:46 AM
  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-28-2026, 09:57 AM
0 responses
36 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-28-2026, 09:51 AM
0 responses
22 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
72 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
48 views
0 reactions
Last Post SEQadmin2  
Working...